Genmab A/S (OTCMKTS:GNMSF) Issues Earnings Results

Genmab A/S (OTCMKTS:GNMSF) issued its earnings results on Wednesday. The company reported $5.70 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $5.24, Zacks reports. Genmab A/S had a net margin of 23.49% and a return on equity of 17.73%.

Genmab A/S Trading Up 8.2 %

Shares of GNMSF traded up $15.78 during midday trading on Friday, reaching $207.62. 30 shares of the stock were exchanged, compared to its average volume of 6,895. Genmab A/S has a 52 week low of $186.61 and a 52 week high of $323.02. The company’s 50 day moving average is $206.28 and its two-hundred day moving average is $230.43. The company has a market capitalization of $13.72 billion, a P/E ratio of 19.96 and a beta of 1.04.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.